 ( Clin Pathol 1999;52:129-136) 
influences the clinical behaviour of these sive Cancer Centre, Amsterdam (n = 56) and lymphomas in terms of overall survival and the St Elizabeth Hospital, Tilburg (n = 3). relapse-free survival time.
ALCL from different sites of origin-that is, lymph nodes (n = 44), gastrointestinal tract Methods (n = 3), and skin (n = 12)-were included.
PATIENT SELECTION
The diagnosis of ALCL was made according Paraffin wax embedded tissue specimens of 59 to the criteria of the updated Kiel classification, primary anaplastic large cell lymphomas were which is also incorporated in the REAL selected from the archives of the Comprehen-classification.227 Patient characteristics are summarised in table 1. The stage of the disease at first presentation was determined by standard staging procedures including full blood count, x rays of the chest, computed tomography of the abdomen, bone marrow aspiration, and biopsy.
Except in three cases, all patients with nodal and gut associated tumours received polychemotherapy consisting of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens, some receiving involved field radiation alone (n = 3) or in addition to chemotherapy (n= 9, 
CYTOTOXIC PHENOTYPE OF ALCL IN RELATION TO IMMUNOPHENOTYPE
It appeared that with two exceptions, all primary skin and gut associated ALCL were CD3+ and CD4+, irrespective of granzyme B/TIA-1 expression, whereas expression of T cell markers in nodal ALCL was found to be more heterogeneous. In nodal granzyme B/TIA-1 positive cases, five CD3+/CD4+/ CD8-cases were found, six cases positive for CD3 only, eight positive for CD4 only, one CD3-/CD4-/CD8+ case, and six CD3-/ CD4-/CD8-cases. These marker profiles did not differ significantly from nodal granzyme B/TIA-1 negative cases: three CD3+/CD4+/ CD8-cases, one case positive for CD3 only, five positive for CD4+ only, and three CD3-/ CD4-/CD8-cases ( granzyme B positive cases, granzyme B could also be demonstrated at the mRNA level in the neoplastic cells in addition to some reactive infiltrating lymphocytes (fig 3) . In cases with granzyme B negative tumour cells, no expression of granzyme B mRNA was detected in the neoplastic cells, whereas some infiltrating lymphocytes did express granzyme B specific mRNA. These data show that granzyme B positive staining of tumour cells is not the result of passive uptake from surrounding nonneoplastic reactive lymphocytes but represents intracellular production.
A vj PATIENT CHARACTERISTICS AND PROGNOSTIC VALUE OF NEOPLASTIC CELLS WITH A CYTOTOXIC PHENOTYPE
The clinical features of the 59 patients are summarised in table 1. When all sites were included, no major differences in clinical presentation were observed between granzyme B+/TIA-1+ cases and granzyme B-/TIA-1-cases. In both groups the majority of patients were between 25 and 50 years of age, with a mean of 46 years. Also no differences in stage at presentation were noticed. Site of first presentation strongly influenced prognosis (table 5) . This ranged from excellent in all cutaneous cases to moderate in nodal cases (five year survival 63%). Two of three patients with a gut associated ALCL died as a result of the disease. As expected, ALK expression in nodal cases was found to be a highly favourable prognostic marker; none of 13 patients with ALK positive ALCL died, whereas 17 of 44 patients with ALK negative ALCL died as result of the disease (p = 0.008).
The presence of a cytotoxic phenotype did not appear to have any impact on prognosis for either overall survival or relapse-free survival time when determined by either Cox regression analysis or by log-rank test. Even when different arbitrary thresholds for a minimum percentage of tumour cells with a cytotoxic phenotype was applied (that is, 5%, 10%, 15%, 20%, 30%, or 50% positive tumour cells), no group with a relatively poor prognosis could be defined (fig 4) . Also, when adjusted for either stage at presentation, site, or ALK status, no differences were found in either overall survival or relapse-free survival time. Since cutaneous ALCL are consistently data are in line with those published by CD3/CD4 positive and CD8 negative, these ics et al and Boulland et al. " 15 Interest-lymphomas may be the neoplastic counterparts the expression of ALK was nearly always of a unique site specific subset of cytotoxic iated with a cytotoxic phenotype and a CD4 positive T cells,'2 whereas nodal cases prognosis. This confirms previous find-may originate from different subsets of potenhat nodal ALCL showing ALK expres-tially cytotoxic T cells. Another possibility is is a separate clinicopathological entity that these cases arise from CD4 positive, CD8 l good prognosis.3 Detection of granzyme negative T cells that acquire a cytotoxic phenothe mRNA level excluded the possibility type on long term antigenic stimulation or on letection of granzyme B expression was activation by the presence of high levels of cersult of passive uptake of granzyme B from tain cytokines.42 One indication that cytokine Lrrounding cytotoxic T cells. levels may be involved in the cytotoxic phenoeoretically, the prognosis of ALCL origi-type of tumour cells is the fact that TIA-1 posir from neoplastic equivalents of (activated) tive tumour cells usually outnumbered the xic T cells should be relatively poor, since number of granzyme B positive tumour cells. cells are themselves resistant to cytotoxic T Cytotoxic T cells express granzyme B only after nduced, and possibly also to treatment activation with interleukin (IL)-2, IL-9, or ed, apoptosis. However, our results clearly IL-i12,"' whereas TIA-1 is expressed in all that the presence of a cytotoxic phenotype potentially cytotoxic cells. Thus differences in aot have any prognostic significance on its local cytokine concentrations might account Even when several arbitrary thresholds for for the differences in activation stage and thus limal percentage of tumour cells with a for the different expression patterns for TIA-1 xic phenotype were applied, no group and granzyme B. 
